logo
  

Addex Therapeutics Says Phase 2 Epilepsy Study Did Not Meet Primary Goal

Addex Therapeutics Ltd (ADXN) Monday said its Phase 2 epilepsy study of ADX71149 in patients with focal onset seizures with suboptimal response to antiepileptic drugs levetiracetam or brivaracetam did not meet primary goal.

The study did not achieve statistical significance for the primary endpoint of time for patients to reach baseline seizure count when ADX71149 was added to standard of care.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Flash inflation and consumer confidence from Germany and monetary aggregates from the euro area are the top economic news due on Wednesday. At 2.00 am ET, the market research group Gfk is scheduled to issue Germany's consumer confidence survey results. The confidence index is forecast to improve to -22.5 in June from -24.2 in May. The International Monetary Fund upgraded China's growth outlook for both 2024 and 2025 citing strong first quarter GDP data and recent policy measures. The Washington-based lender expects the economy to grow 5 percent this year, which was up from 4.6 percent projected in April. Likewise, the outlook... After moving in opposite directions early in the session, the Nasdaq and the Dow turned in a mixed performance throughout much of the trading day on Tuesday. While the Nasdaq briefly joined the Dow in negative territory in afternoon trading, the tech-heavy index rebounded to end the day at a new record closing high.

Minutes of the latest Fed policy session dominated the economics scene this week. Find out what made policymakers give a “higher for longer” signal on interest rates. In Europe, the main news out this week was the inflation print from the U.K. Learn how the data was bad news for those hoping for an imminent rate cut from the Bank of England. Also, explore why New Zealand's central bank also hinted at a delay in its plans for interest rate reduction in future.

View More Videos
Follow RTT